CD18 trials disappoint again

  title={CD18 trials disappoint again},
  author={Alan W. Dove},
  journal={Nature Biotechnology},
  • A. Dove
  • Published 1 August 2000
  • Medicine, Biology
  • Nature Biotechnology
Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
JAK2-V617F, the most prevalent mutation in MPNs, has been shown to activate a number of integrins on mature myeloid cells, including granulocytes and erythrocytes, which increase adhesion and drive venous thrombosis in murine knock-in/out models.
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Targeting MDSCs as a therapeutic approach in cancer therapy is examined, with a special focus on GB1275 preclinical studies laying the rationale for the phase 1/2 clinical study.
Myeloid Cell Mediated Ilmmune Suppression in Pancreatic Cancer
Thromboinflammation Model-on-A-Chip by Whole Blood Microfluidics on Fixed Human Endothelium
A thromboinflammation model which uses straight channels, lined with fixed human umbilical vein endothelial cells, after treatment with tumour necrosis factor-alpha and offers the advantage of the use of fixed endothelium, whole blood, instead of isolated neutrophils, and a small amount of blood.
TIME Is a Great Healer—Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes
This review will focus on macrophages as well as the phenotypes they acquire with the tumor immune microenvironment (TIME) in triple-negative breast cancer (TNBC).
Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations
The pathophysiological reasoning behind therapeutic CRP apheresis is explained and the broad span of indications in which its application could be beneficial with a focus on ischemic stroke is summarized as well as the results of this therapeutic approach after myocardial infarction are summarized.
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
This study identifies collagen and LAIR1 as potential markers for immunotherapy resistance and validates multiple promising therapeutic combinations.
15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one sensitizes rectal tumor cells to anti-PD1 treatment through agonism of CD11b
Activation of CD11b with 15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one (HESEO) enhanced the therapeutic efficacy of anti-PD1 treatment in the tumor model, providing proof of concept for a new combination strategy involving molecular agonism ofCD11b to bypass the limitations of current clinical strategies to overcome resistance to immunotherapies.
Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer
Findings suggest that positive allosteric modulation of CD11b reduces TAM density and reprograms them to enhance the adaptive immune response and is a novel therapeutic strategy against lung cancer.
LFA-1 Controls Th1 and Th17 Motility Behavior in the Inflamed Central Nervous System
The results show that LFA-1 plays a pivotal role in T cell Motility during EAE and suggest that interfering with the molecular mechanisms controlling T cell motility can help to reduce the pathogenic potential of autoreactive lymphocytes.